John Patrick Oroho

Principal

vCard
Print
Share with:

Overview

John Patrick Oroho is a principal of Porzio, Bromberg & Newman in the Life Sciences Compliance and Regulatory Counseling Department. His practice is concentrated in the areas of regulatory compliance with respect to Aggregate Spend, Physician Payment Sunshine Act, the Prescription Drug Marketing Act (“PDMA”), Antikickback Statute, False Claims Act, and Medicare and Medicaid fraud and abuse. Mr. Oroho is a noted expert on pharmaceutical compliance, specifically OIG and state compliance with Sales and Marketing and product distribution. He has written and lectured extensively on these, as well as other life science compliance issues. He has worked with companies under Corporate Integrity Agreements to ensure their compliance with the standards established for pharmaceutical marketing and sales. Mr. Oroho previously served as Senior Vice President and General Counsel for the PDMA Alliance, a national trade association focused on sample distribution and pharmaceutical marketing and sales compliance. Mr. Oroho has been responsible for the development of Aggregate Spend systems and PDMA-compliant sample tracking systems.

Mr. Oroho is also Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC, a wholly owned subsidiary of the law firm. He meets regularly with companies to identify sales and marketing issues and to propose solutions that streamline their understanding of acceptable practices and conduct in meeting compliance requirements of all 50 states and the District of Columbia.

Recognition

No aspect of this advertisement has been approved by the Supreme Court of New Jersey. Prior results do not guarantee a similar outcome. 

  • Recognized in Who's Who Legal – Compendium Edition, 2017; Who's Who Legal: Life Sciences - Regulatory, 2016; Who's Who Legal: Life Sciences, 2015.
    A description of the selection process can be found here.
  • "European Healthcare Compliance Certification," Seton Hall European Healthcare Compliance Program, Paris, France, November 12 - November 16, 2012.
    A description of the selection process can be found here

Memberships

  • American Bar Association
  • PDMA Alliance
  • Family Resource Network, Board of Trustees
  • Catholic Academy of Sussex County, Board of Trustees
  • Federal Academy Selection Committee for Congressman Scott Garrett (R-NJ)
  • University of Notre Dame Law Association
  • The United States Merchant Marine Academy Alumni Association

Speaking Engagements

  • "Mini Summit 8: Global Update on HCP Transparency Reporting/Aggregate Spend," Speaker, 15th International Pharmaceutical and Medical Device Ethics & Compliance Congress, Virtual , 5/17/2022
  • "Compliance Top 10 – Clear and Concise Overview of the Top Areas of Concern for the Compliance Professional," Speaker, Pharmaceutical Compliance Congress, McLean, VA, 4/25/2022
  • "Panel Discussion: Ask the Experts – What Keeps You Up at Night?" The latest in Drug Pricing Transparency Requirements, Panelist, Philadelphia, PA, 3/28/2022
  • "Explore Prosecutor Perspectives on the High-Risk Activities of Speaker Programs," Moderator, Virtual Speaker Programs Summit, 2/16/2022
  • "Open Forum for Benchmarking, Q&A and Best Practice Sharing," Transparency & Aggregate Spend Conference , 12/07/2021
  • "Back to the Future of Medical Meetings," Webinar, MPI MedUP Town Hall, 11/30/2021
  • "Changing Dynamics of State Price Transparency and Reporting Requirements," Virtual 22nd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, 11/03/2021
  • "Internal Adoption of Innovation by Law Firms," Baretz & Brunelle NewLaw Practice Report, Webinar, 10/28/2021
  • "Operationalizing Compliance Guidance - Key Learnings for DOJ Updates, OIG Fraud Alert and Open Payments Enforcement Action,"  Speaker, Pharmaceutical Compliance Congress, 9/28/2021
  • "Navigating State, Federal & International Transparency Disclosure Requirements," Seton Hall U.S.. Healthcare Compliance Certificate Program, Speaker, 6/14/2021
  • "Implementing Safe, Compliant and Successful Direct-to-Patient (DTPt) Sampling Programs," Pharmaceutical Commerce, Sponsored by J. Knipper and Company, On-Demand Webcast, 5/26/2021
  • "2021 Life Sciences Compliance Outlook," Porzio Life Sciences, Webinar, 3/16/2021
  • "Transition of Medical and Healthcare Meetings in 2021," Medical and Healthcare Professionals 2021 Series Kick-Off Webinar, 2/12/2021
  • "Enforcement and Industry Panel Discussion," Virtual 14th Annual Forum on Transparency, Aggregate Spend and HCP Engagement, 12/09/2020
  • "Changing Dynamics of State Price Transparency and Reporting Requirements," Virtual 21st Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, Mini Summit XIV, 11/05/2020
  • "Navigating State, Federal & International Transparency Disclosure Requirements," Seton Hall U.S. Healthcare Compliance Certificate Program, 10/12/2020
  • "Racing Toward a Vaccine," Update on the efforts by New Jersey's life sciences business community to develop a vaccine for COVID-19, Morris County Chamber of Commerce and Morris County Economic Development Corporation (MCEDC), 9/29/2020
  • "A Look at How In-House Legal & Compliance Departments are Evolving in 2020 to Help Address Business Challenges," 17th Annual Pharmaceutical Compliance Congress 2020, 8/13/2020
  • "Coronavirus Dialogue Series:  Medical Meetings Post COVID-19," Meeting Professionals International Life Sciences Webinar, 6/17/2020
  • "The Evolution of Compliant HCP Engagements and Transparency: Your Guide to the Past, Present, and Future," PCC Webcast Series - Pharmaceutical Compliance Digital Week, 5/21/2020
  • "How Vulnerable are Medical Meetings both in the Short Term and Long Term?" Market Transformation Series, Life Sciences Meetings Webinar, 5/18/2020
  • "Navigating State, Federal & International Transparency Disclosure Requirements," U.S. Healthcare Compliance Certificate Program, Seton Hall Law, 10/14/2019
  • "State Drug Pricing Transparency Level-Set – Reporting and Requirements Landscape,"  5th Edition Drug Pricing Transparency, 9/19/2019
  • "Address the Recent Trends in State-By-State/City-By-City Reporting and How to Keep on the Pulse of Change," Panel Discussion, Moderator, The 13th Annual Forum on Transparency and Aggregate Spend, 8/13/2019
  • "Prepare for the Future State of Transparency in Canada – Lessons Learned From Europe and The U.S.," Pharmaceutical Compliance Congress Canada, 6/11/2019
  • "Operationalize Emerging Global Reporting Requirements," CBI's 2nd Annual U.S.-Based Congress on Global Transparency Reporting  , 5/15/2019
  • "Summit Host Welcome and Anti-Trust Guideline Reminders," CBI's 16th Annual Pharmaceutical Compliance Congress, 4/17/2019
  • "Transparency Meets HCP Engagement," Synergistix Users Collaboration Conference 2019 Prescription for Success\, 4/04/2019
  • "Keeping Track of the Evolving Laws Impacting Compliance and HCP Interactions," CBI's 4th Edition Drug Pricing Transparency Congress, 3/26/2019
  • "Tracking Federal, State, Local and Global Laws Impacting HCP Interactions Compliance & Reporting," 7TH Annual Global Pharmaceutical and Medical Meetings Summit, 2/05/2019

Prior Relevant Experience

  • Integrated Pharma Technologies, General Counsel & Director of Operations, 2002–2003
  • Computer Systems Services & Consulting, General Counsel and Director of Business Development, 2000–2002
  • Struble Ragno Petrie Oroho Spinato Bonanno MacMahon & Conte, P.C., Senior Partner, 1989–2000
  • Bruinooge & Associates, Associate, 1987–1989
  • Riker, Danzig, Scherer, Hyland & Perretti, Associate, 1987
  • Fulbright & Jaworski, Associate, 1985–1987